Copy
See below for a weekly digest of the latest Cystic Fibrosis news:

Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment

Mar 29, 2019 07:00 am | Ana Pena



ELX-02 preclinical dataEloxx Pharmaceuticals presented new positive preclinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), demonstrating that the therapy increases the levels of CFTR protein and its correct placement at the cell’s surface in patient-derived organoids. Findings were presented by Shira Landskroner-Eiger, PhD, Eloxx’s principal scientist at the 2019 European Cystic Fibrosis Society (ECFS) […]

The post Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment appeared first on Cystic Fibrosis News Today.

Read More
share on Twitter Like Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment on Facebook

My Body Is Not Always a Temple: Work-life Balance with CF

Mar 28, 2019 09:00 am | Elly Aylwin-Foster



bodyMany young professionals burn the candle at both ends, especially when the temptation to fit into a big city’s lifestyle lurks. Somehow, they continue to function as productive humans — for the most part. But a person with cystic fibrosis (CF) and those in their trusted circle know that holding down a job and taking […]

The post My Body Is Not Always a Temple: Work-life Balance with CF appeared first on Cystic Fibrosis News Today.

Read More
share on Twitter Like My Body Is Not Always a Temple: Work-life Balance with CF on Facebook

Costs for CF Therapies Could Double in 2019, According to Pharmacy Benefit Manager

Mar 28, 2019 07:00 am | Santiago Gisler



therapy costsCosts for approved cystic fibrosis (CF) treatments and new approvals — including therapies extended to more age groups or targeting new mutations — could double in price, according to pharmacy benefit manager (PBM) Prime Therapeutics. The cost increases could result in higher premiums for Prime members. According to the company, the forecast comes as a […]

The post Costs for CF Therapies Could Double in 2019, According to Pharmacy Benefit Manager appeared first on Cystic Fibrosis News Today.

Read More
share on Twitter Like Costs for CF Therapies Could Double in 2019, According to Pharmacy Benefit Manager on Facebook
 

Recent News

Triple Combo of Proteostasis’ CFTR Modulators May Benefit CF Patients, Phase 1 Trial Shows
‘CFer’ or ‘Person with CF’? I’m a CFer and Proud of It
Asthma Medicine Xolair Successfully Treats Lung Allergy Due to Fungal Infection in 3 CF Patients, Case Report Shows
How We Capitalize on ‘Five Feet Apart’
Targeting Bacteria Cell Wall Elements Can Fight Chronic P. aeruginosa Infection, Study Suggests

Copyright © 2019 BioNews Services, LLC, All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences